Drug manufacturer Lilly indicated late last week that it reserves the right to seek additional compensation for its products from 340B covered entities if it learns later that it charged them less than what the company perceives the 340B statute
…
Articles by : Tom Mirga, Editor at Large
America’s Essential Hospitals and 340B Health yesterday denounced GlaxoSmithKline’s (GSK) new restrictions on 340B pricing when hospitals use contract pharmacies. Pharmaceutical Research and Manufacturers of America (PhRMA) said this morning it will keep pushing for “much needed changes” to
…
UPDATE Monday, Feb. 14, 2022, 1:30 p.m. EST—The U.S. Health Resources and Services Administration (HRSA) said, “We are reviewing GSK’s policy and will evaluate next steps as needed.”
Drug manufacturer GlaxoSmithKline (GSK) told 340B covered entities this morning that effective
…
President Joe Biden today during a major speech on drug pricing reform applauded U.S. Rep. Abigail Spanberger (D-Va.) for being “relentless in making sure” that the 340B statute “is actually enforced.”
Biden and U.S. Health and Human Services (HHS) Secretary
…
AIDS Healthcare Foundation (AHF) today criticized efforts to introduce federal legislation to address drug manufacturers’ denials of 340B pricing when covered entities use contract pharmacies. It said the drug industry “will certainly use any legislation as an opportunity to further
…
President Joe Biden and U.S. Health and Human Services (HHS) Secretary Xavier Becerra are scheduled to speak on Monday, Feb. 14, during the National Association of Community Health Centers’ Policy and Issues Virtual Forum, NACHC announced on Tuesday.
Securing Biden
…
Drug manufacturer GlaxoSmithKline is providing refunds for charges above 340B ceiling prices on nine NDCs for purchases during Q1 2020.
GSK posted a public notice about the repayments on the U.S. Health Resources and Services Administration web site this
…
The U.S. Health Resources and Services Administration (HRSA) said yesterday it knows of three hospitals that have withdrawn from the 340B program because changes in patient mix linked to the COVID-19 pandemic caused them to lose their eligibility. There could
…
Prospects for passage of Democratic drug pricing legislation as part of the Build Back Better (BBB) Act dimmed again last week with news that Sen. Ben Ray Lujan (D-N.M.) had a stroke on Jan 27.
Lujan’s chief of staff
The National Association of Community Health Centers (NACHC) told Republican members of Congress last week that “congressional action may be the only solution” to drug makers’ “aggressive actions to limit patients’ access to affordable medications at contract pharmacies.”
NACHC’s